ESC 365 - Mavacamten in hypertrophic cardiomyopathy: use of accessible functional testing to examine real-world effectiveness

ESC2025 Premium Access

Mavacamten in hypertrophic cardiomyopathy: use of accessible functional testing to examine real-world effectiveness

Session: Management of hypertrophic obstructive cardiomyopathy

Topic: Hypertrophic Cardiomyopathy

Speaker: Doctor M. Todd (Belfast, GB)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Matthew Todd

Belfast Health and Social Care Trust, Belfast (United Kingdom of Great Britain & Northern Ireland)

0 follower

6 more presentations in this session

Ablation scar at the his-bundle area predicts persistent complete atrioventricular block requiring pacemaker after alcohol septal ablation for obstructive hypertrophic cardiomyopathy

Speaker: Doctor T. Kawai (Tokyo, JP)

Effect of mavacamten on left ventricular myocardial volume, strain and tissue characteristics in patients with hypertrophic cardiomyopathy

Speaker: Doctor J. Tse (Calgary, CA)

Hemodynamic and symptomatic response in real-world patients with hypertrophic obstructive cardiomyopathy and myosin inhibitor therapy

Speaker: Mr A. Feidakis (Cologne, DE)

Real-world symptom and echocardiographic improvement in obstructive HCM patients treated with mavacamten: evidence of favorable disease modification

Speaker: Doctor M. Desai (Cleveland, US)

Effect of Mavacamten on left ventricular diastolic function and left atrial function in obstructive hypertrophic cardiomyopathy

Speaker: Doctor N. Cohen (Marseille, FR)

Access the full session

Management of hypertrophic obstructive cardiomyopathy

Speakers: Doctor M. Todd, Doctor T. Kawai, Doctor J. Tse, Mr A. Feidakis, Doctor M. Desai...

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources